Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $62.50.
JSPR has been the topic of several analyst reports. UBS Group initiated coverage on Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock.
Read Our Latest Analysis on Jasper Therapeutics
Institutional Trading of Jasper Therapeutics
Jasper Therapeutics Trading Up 2.0 %
JSPR opened at $5.49 on Monday. The company has a market cap of $82.47 million, a P/E ratio of -1.16 and a beta of 2.23. The business’s 50-day moving average price is $6.45 and its 200-day moving average price is $15.78. Jasper Therapeutics has a 12 month low of $4.55 and a 12 month high of $31.01.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Equities research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.
About Jasper Therapeutics
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Further Reading
- Five stocks we like better than Jasper Therapeutics
- What is the FTSE 100 index?
- How to Build the Ultimate Everything ETF Portfolio
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Where Do I Find 52-Week Highs and Lows?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.